Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 19, 2016. The document serves as a transaction notification regarding a specific securities transaction involving a Person Discharging Managerial Responsibilities (PDMR) or a person closely associated with them.
Key Financial Metrics
The filing does not provide consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It reports solely on a specific transaction involving American Depositary Shares (ADSs).
| Metric | Value |
|---|---|
| Instrument | American Depositary Shares (ADSs) |
| Transaction Type | Acquisition via dividend re-investment |
| Transaction Date | July 14, 2016 |
| Price per ADS | $43.87 |
| Total Volume | 337.852 ADSs |
| Exchange | New York Stock Exchange (XNYS) |
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It details an acquisition of 337.852 ADSs by Mr. D R Troy (SVP & General Counsel) following the re-investment of dividends paid on July 14, 2016, under the Company's US Deferred Performance Share Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, outlook, risk factors, or contingencies. It is a regulatory disclosure of a specific insider transaction.
Key Facts for Investor Verification
- The transaction was an acquisition of ADSs by a senior executive (SVP & General Counsel) via dividend re-investment.
- The transaction occurred on July 14, 2016, at a price of $43.87 per ADS.
- The total volume acquired was 337.852 ADSs.
- This filing does not contain financial performance data for the company.